Innovations in antineoplastic therapy

Nursing Clinics of North America

Volumn 40, Issue 1, 2005, Pages 77-94

  Kaplow, Roberta ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABARELIX; ALEMTUZUMAB; ANASTROZOLE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; ARSENIC TRIOXIDE; BEVACIZUMAB; BORTEZOMIB; CAPECITABINE; CARMUSTINE; CARMUSTINE PLUS POLIFEPROSAN; CETUXIMAB; CISPLATIN; DOCETAXEL; EXEMESTANE; FEMERA; FLUDARABINE PHOSPHATE; FLUOROURACIL; FOLINIC ACID; FULVESTRANT; GEFITINIB; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; IMATINIB; IRINOTECAN; LETROZOLE; LEUPRORELIN; MONOCLONAL ANTIBODY; OBLIMERSEN; OXALIPLATIN; RITUXIMAB; TOSITUMOMAB; TOSITUMOMAB I 131; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABDOMINAL PAIN; AGITATION; ALLERGIC REACTION; ALOPECIA; ANAPHYLAXIS; ANEMIA; ANOREXIA; ANXIETY; ARTHRALGIA; ARTHRITIS; ASTHENIA; AUTOIMMUNE HEMOLYTIC ANEMIA; BACKACHE; BLOOD EXAMINATION; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BRAIN ABSCESS; BRAIN CYST; BRAIN EDEMA; BRAIN HEMORRHAGE; BRAIN INFARCTION; BRONCHOSPASM; CANCER CELL; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CHILL; CLINICAL TRIAL; COLORECTAL CANCER; CONFUSION; CONSTIPATION; COUGHING; DEHYDRATION; DEPRESSION; DIARRHEA; DIPLOPIA; DROWSINESS; DRUG APPROVAL; DRUG DOSAGE FORM; DRUG EFFICACY; DYSPNEA; EDEMA; ENDOMETRIUM CANCER; EPISTAXIS; EYE PAIN; FATIGUE; FEVER; FLU LIKE SYNDROME; FLUID RETENTION; FRACTURE; GASTROENTERITIS; GASTROINTESTINAL HEMORRHAGE; GYNECOMASTIA; HEADACHE; HEART ARRHYTHMIA; HEMATEMESIS; HEMOPTYSIS; HORMONAL THERAPY; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; HYPERHIDROSIS; HYPERSENSITIVITY REACTION; HYPERTENSION; HYPOTENSION; INFECTION; LEUKEMIA; LIFE EXPECTANCY; LIVER INJURY; LUNG NON SMALL CELL CANCER; MALAISE; MASTALGIA; MENTAL INSTABILITY; MORBIDITY; MOUTH INFLAMMATION; MOUTH ULCER; MUSCLE CRAMP; MUSCLE WEAKNESS; MYALGIA; NAUSEA; NEUROPATHY; NEUTROPENIA; NIGHT SWEAT; NONHUMAN; NURSING; PAIN; PANCYTOPENIA; PARESTHESIA; PATIENT COMPLIANCE; PERIODIC MEDICAL EXAMINATION; PHARYNGITIS; PLEURA EFFUSION; PNEUMONIA; POLYDIPSIA; PRURITUS; QT PROLONGATION; RASH; RESPONSIBILITY; REVIEW; RHINITIS; RIGIDITY; SEIZURE; SEPSIS; SIDE EFFECT; SKIN MANIFESTATION; SORE THROAT; STOMATITIS; THROMBOCYTOPENIA; TUMOR LYSIS SYNDROME; VAGINA BLEEDING; VAGINA DISCHARGE; VAGINAL DRYNESS; VEIN THROMBOSIS; VISUAL DISORDER; VISUAL IMPAIRMENT; VOMITING; WEIGHT GAIN; WOUND INFECTION; XEROSTOMIA;

EID: 14744301674     PISSN: 00296465     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cnur.2004.08.007     Document Type: Review

References (44)

1. H.S. Hochster Opportunities for newer agents in combination with oxaliplatin Semin Oncol 30 4 Suppl 15 2003 62 67
2. National Cancer Institute. Available at: http://www.cancer.gov. Accessed December, 2003.
3. Doctor's Guide Channel. Available at http://www.docguide.com. Accessed November, 2003.
4. Food and Drug Administration. Available at: http://www.fda.gov. Accessed December, 2003.
5. R. Abou-Jawde, T. Choueiri, C. Alemany, and T. Mekhail An overview of targeted treatments in cancer Clin Ther 25 8 2003 2121 2137
6. C. Gridelli, A. Rossi, and P. Maione Treatment of non-small-cell lung cancer: state of the art and development of new biologic agents Oncogene 22 42 2003 6629 6638
7. D.M. Gale Molecular targets in cancer therapy Semin Oncol Nurs 19 3 2003 193 205
8. Cancer BACUP. Available at: http://www.cancerbacup.org. Accessed December, 2003.
9. Lymphoma Information Network. Available at: http://www.lymphomaininfo. net. Accessed December, 2003.
10. National Cancer Institute. Available at: http://www.nci.nih.gov. Accessed December, 2003.
11. American Pharmacists Association and National Association of Boards of Pharmacy. Available at: http://www.pharmacist.com. Accessed December, 2003.
12. B. Mavromatis, and B.D. Chesen Monoclonal antibody therapy for chronic lymphocytic leukemia J Clin Oncol 21 9 2003 1874 1881
13. Center Watch. Clinical Trials Listing Service. Available at: http://www.centerwatch.com. Accessed December, 2003.
14. K. Lyseng-Williamson, and B. Jarvis Imatinib Drugs 61 12 2001 1765 1774
15. D.G. Savage, and K.H. Antman Drug therapy: imatinib mesylate-a new oral targeted therapy N Engl J Med 346 9 2002 683 693
16. B.J. Druker, M. Talpuz, D.J. Resta, B. Peng, E. Buchdunger, and J.M. Ford Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia N Engl J Med 19 3 2001 193 205
17. P. Ault, S. Kaled, and M.B. Rios Management of molecular-targeted therapy for chronic myelogenous leukemia J Am Acad Nurse Pract 15 7 2003 292 296
18. E. van Vlaanderen What happened to the "glee" in Gleevac? Clin Advis 6 1 2003 42 48
19. Multiple Myeloma Research Foundation. Available at: http://www. multiplemyeloma.org. Accessed December, 2003.
20. F.R. Applebaum Update on treatment for acute myeloid leukemia Oncology Special Edition 6 2003 45 49
21. W.H. Miller, H.M. Schipper, J.S. Lee, J. Singer, and S. Waxman Mechanisms of action of arsenic trioxide Cancer Res 62 14 2002 3893 3903
22. J. Baselga Why the epidermal growth factor receptor? The rationale for cancer therapy Oncologist 7 Suppl 4 2002 2 8
23. P.A. Spencer-Cisek The role of growth factors in malignancy: a focus on the epidermal growth factor receptor Semin Oncol Nurs 18 2 Suppl 2 2002 13 19
24. S.S. Sridhar, L. Seymour, and F.A. Shephard Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer Lancet Oncol 4 7 2003 397 406
25. E.S. Waxman, and R.S. Herbst The role of epidermal growth factor receptor in the treatment of colorectal carcinoma Semin Oncol Nurs 18 2 Suppl 2 2002 20 29
26. J. Riddle, P. Lee, and M. Purdom The epidermal growth factor receptor as a novel target for cancer therapy: case studies and clinical implications Semin Oncol Nurs 18 4 Suppl 4 2002 11 19
27. Parker Hughes Cancer Center. Available at: http://www.ih.org. Accessed December, 2003.
28. R.S. Herbst, P.M. LoRusso, M. Purdom, and D. Ward Dermatologic side effects associated with gefitinib therapy: clinical experience and management Clin Lung Cancer 4 6 2003 366 369
29. R. Herbst, and C. Langer Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers Semin Oncol 1 Supp 4 2002 27 36
30. F. Ciardiello, and G. Tortora A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor Clin Cancer Res 7 2001 2958 2970
31. B.A. Caley, and F. Reidenbach Expanding options for advanced breast cancer Cure 2 3 2003 47 54
32. Breastcancer.org. Available at: http://www.breastcancer.org. Accessed December, 2003.
33. A. Buzdar Anastrozole as adjuvant therapy for early-stage breast cancer: implications of the ATAC trial Clin Breast Cancer 4 Suppl 1 2003 S42 S48
34. National Alliance of Breast Cancer Organizations. Available at: http://www.nabco.org. Accessed December, 2003.
35. J. Bryant, and N. Wolmark Letrozole after tamoxifen for breast cancer - what is the price of success? N Engl J Med 349 19 2003 1855 1857
36. War On Cancer. Available at: http://www.witts.org. Accessed November, 2003.
37. M. Juweid Technology evaluation: epratuzumab, immunogenics/amgen Curr Opin Mol Ther 5 2 2003 192 198
38. R.J. Klasa, A.M. Gillum, R.E. Klem, and S.R. Frankel Oblimersen bcl-2 antisense: facilitating apoptosis in anticancer treatment Antisense Nucleic Acid Drug Dev 12 3 2002 193 213
39. Multiple Myeloma Research Foundation. Available at: http://www. multiplemyeloma.org. Accessed December, 2003.
40. B. Jansen, and U. Zangemeister-Wittke Antisense therapy for cancer - the time of truth Lancet Oncol 3 11 2002 672 683
41. J.S. Waters, A. Webb, D. Cunningham, P.A. Clarke, F. Raynaud, and F. di Stefano Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma J Clin Oncol 18 2000 1812 1823
42. PSL Group. Available at: http://www.pslgroup.com. Accessed December, 2003.
43. H.W. Waksal Role of an anti-epidermal growth factor receptor in treating cancer J Clin Oncol 20 2002 719 726
44. D.M. Stull Targeted therapies for the treatment of leukemia Semin Oncol Nurs 19 2 2003 90 97